Major Players - Tuberculosis Drugs Industry

The burden of tuberculosis (TB), a chronic disease, has spread throughout the world. Drug producers working to treat TB are concentrating on creating medicines that can reduce the length of therapy and aid in the fight against drug-susceptible and drug-resistant TB. First line treatment, second line treatment, and drug resistant treatment are three categories of TB treatment. With the help of currently accessible drugs, the majority of TB cases can be treated for up to 6 months. The time it takes to treat TB is expected to decrease thanks to technological developments and the creation of new treatments. However, there is still a need to expand patients' access to the right TB medications, particularly in the cases of pediatric and MDR TB. This is valid despite current treatments and ongoing improvements in TB medications. As a result of an increase in medicinal discoveries, the market for drugs that treat tuberculosis is growing. The nonprofit TB Alliance in the United States has developed a breakthrough drug to treat tuberculosis strains that are incredibly resistant to current treatments. Participants in the sector are also focusing on strategic relationships to promote their most recent medications. Due to the widespread prevalence of TB around the world, the market for TB drugs is growing.

The global market for Tuberculosis Drugs  is projected to grow at a CAGR of 5.3% from 2019 to 2027.

 Leading Companies in the Tuberculosis Drugs Industry:

1. Johnson & Johnson Services, LLC

Johnson & Johnson Services, LLC was founded in 1886 and headquartered in New Jersey, U.S. It operates in 60 countries and products sold in over 175 countries. In March, 2022, World Tuberculosis (TB) Day, Johnson & Johnson India (the Company) announced the launch of a youth-focused, digital-first initiative called #BeTheChangeForTB. This was part of the Company's commitment to the Corporate TB Pledge, which is a joint effort with the Central TB Division, Ministry of Health and Family Welfare in India, and the United States Agency for International Development (USAID) to help India reach its goal of ending TB.

2. Lupin Ltd

Lupin Ltd is an Indian multinational pharmaceutical company, was founded in 1968 and headquartered in Maharashtra, India. It operates in more than 100 countries. In September 2021, Lupin and the TB Alliance will work together to make a new treatment for drug-resistant tuberculosis. Mel Spigelman, president and chief executive officer of TB Alliance, said that working with Lupin, a well-known company that has experience making high-quality TB treatments, will help more people get access to the new plan and make it more affordable.

3. Novartis AG

     Novartis AG is a Swiss multinational pharmaceutical corporation founded in 1996 and is headquartered in Basel, Switzerland. It operates in 140 countries.

4. Macleods Pharmaceuticals Ltd

     Macleods Pharmaceuticals Ltd was founded in 1986 and headquartered in Maharashtra, India. It operates in over 170 countries. In April 2023, Natco Pharma and MacLeods Pharmaceuticals are prepared to release their versions of Bedaquiline, the revolutionary Tuberculosis (TB) drug developed by Johnson & Johnson.

5. Otsuka Pharmaceutical Co., Ltd

     Otsuka Pharmaceutical Co., Ltd was founded in 1921 (originally founded), and headquartered in Tokyo, Japan. It operates in 33 countries. The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) cooperation signs a joint development agreement (JDA) in August 2022 to advance two experimental TB combination therapy regimens into phase 2 clinical development. The collaboration will test whether novel regimens, which combine registered products and new chemical entities (NCEs), can treat all forms of active pulmonary TB in much shorter time than current drug regimens. The goal is to find a regimen suitable for phase 3 development.

6. Pfizer Inc

Pfizer Inc is an American multinational pharmaceutical and biotechnology corporation founded in 1849 and headquartered in New York City, United   States. It operates in 181 countries. In November 2019, Pfizer and the Medicines Patent Pool signed a licensing deal for sutezolid, a TB drug that isbeing tested by the US company. The move should help get the product to  market faster, since its development seems to have stopped in 2013.

Definition:

Tuberculosis is a potentially serious infectious bacterial disease that mainly affects the lungs. The bacteria that cause TB are spread when an infected person coughs or sneezes. Most people infected with the bacteria that cause tuberculosis don't have symptoms.